MSFT 418.16 1.6283% AAPL 224.066 0.2757% NVDA 145.9801 4.3386% GOOGL 175.86 3.6055% GOOG 177.66 3.6462% AMZN 205.4572 2.9861% META 566.026 -1.1187% AVGO 177.99 2.3519% TSLA 287.7499 14.4408% TSM 193.2121 -1.3015% LLY 771.5099 -4.2863% V 306.11 4.3711% JPM 245.82 10.9847% UNH 595.095 4.9495% NVO 105.84 -3.8954% WMT 82.485 -1.4281% LVMUY 129.51 -1.5133% XOM 121.57 2.194% LVMHF 647.52 -1.7271% MA 520.12 2.88%
Last update at 2024-11-06T14:30:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -6.31253M | -6.72840M | -3.26488M | -2.44034M | -2.13313M |
| Minority interest | - | - | - | - | - |
| Net income | -6.30471M | -6.73518M | -3.26332M | -2.39062M | -2.13313M |
| Selling general administrative | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| Reconciled depreciation | - | - | - | - | - |
| Ebit | -6.31148M | -6.72044M | -3.26644M | - | -2.14790M |
| Ebitda | -6.30029M | -6.71982M | -3.26121M | -2.49007M | -2.13805M |
| Depreciation and amortization | 0.01M | 0.00063M | 0.00523M | - | 0.00985M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -6.31148M | -6.72044M | -3.26644M | -2.49007M | -2.13805M |
| Other operating expenses | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M |
| Interest expense | 0.00887M | 0.00741M | 0.00367M | 0.05M | 0.00492M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.01M | 0.00063M | 0.00156M | 0.05M | 0.00492M |
| Net interest income | 0.00232M | -0.00679M | 0.00156M | 0.05M | 0.00492M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.00782M | 0.00679M | -0.00156M | -0.04972M | -0.00985M |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | -0.00105M | -0.00795M | 0.00156M | 0.05M | 0.00492M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -6.31253M | -6.72840M | -3.26488M | -2.44034M | -2.13313M |
| Net income applicable to common shares | - | - | -3.26488M | -2.44034M | -2.13313M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 4.31M | 5.56M | 5.09M | 5.23M | 2.67M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.03M | 0.01M | 0.01M | 0.01M | 0.06M |
| Total liab | 0.31M | 0.39M | 0.30M | 0.22M | 0.24M |
| Total stockholder equity | 3.99M | 5.17M | 4.79M | 5.01M | 2.43M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.31M | 0.39M | 0.30M | 0.01M | 0.24M |
| Common stock | 0.00022M | 0.00166M | 0.00137M | 0.00124M | 0.00670M |
| Capital stock | 3.50M | 3.50M | 3.50M | 3.50M | 3.51M |
| Retained earnings | -48.48173M | -43.39470M | -37.08216M | -30.35377M | -27.08889M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 4.20M | 5.35M | 4.82M | 5.07M | 2.60M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 0.31M | 0.39M | 0.30M | 0.22M | 0.24M |
| Current deferred revenue | 0.16M | 0.17M | 0.08M | 0.02M | 0.09M |
| Net debt | -4.20349M | -5.35339M | -4.82374M | -5.06927M | -2.59886M |
| Short term debt | 0.31M | -0.39479M | -0.30293M | - | -0.23790M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | 48.98M | 45.06M | 38.37M | 31.86M | 26.02M |
| Property plant equipment | - | - | - | - | - |
| Total current assets | 4.23M | 5.56M | 5.09M | 5.23M | 2.67M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | - | - |
| Short term investments | - | - | - | - | - |
| Net receivables | - | - | - | - | 0.01M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 0.16M | 0.23M | 0.23M | 0.19M | 0.14M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.00022M | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 3.50M | 0.00670M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.08M | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.08M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | - | - | - | - | - |
| Change to liabilities | - | - | - | - | - |
| Total cashflows from investing activities | - | - | - | - | - |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 5.14M | 3.90M | 4.60M | 0.00000M | 4.48M |
| Change to operating activities | - | - | - | - | - |
| Net income | -6.31253M | -6.72840M | -3.26488M | -2.44034M | -2.13313M |
| Change in cash | 0.53M | -0.24552M | 2.47M | -1.67415M | 2.97M |
| Begin period cash flow | 4.82M | 5.07M | 2.60M | 4.27M | 1.31M |
| End period cash flow | 5.35M | 4.82M | 5.07M | 2.60M | 4.27M |
| Total cash from operating activities | -4.61174M | -4.14292M | -2.13141M | -1.67415M | -1.51103M |
| Issuance of capital stock | 5.14M | 3.69M | 4.60M | 0.00000M | 4.50M |
| Depreciation | - | - | - | - | - |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | 0.01M | - | - |
| Sale purchase of stock | - | - | 4.60M | - | 4.48M |
| Other cashflows from financing activities | 5.14M | 0.21M | - | - | -0.02170M |
| Change to netincome | - | - | - | - | - |
| Capital expenditures | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.15M | -0.01344M | -0.11788M | 0.02M | -0.16352M |
| Stock based compensation | 1.55M | 2.60M | 1.25M | 0.75M | 0.79M |
| Other non cash items | -1.54604M | 2.60M | -2.69570M | 1.71M | -3.29201M |
| Free cash flow | -4.61174M | -4.14292M | -2.13141M | -1.67415M | -1.51103M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | ||
|---|---|---|---|---|---|---|---|---|
| LIXTW Lixte Biotechnology Holdings Inc |
0.02 85.39% | 0.05 | - | - | - | - | ||
| NVO Novo Nordisk A/S |
-4.29 3.90% | 105.84 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
5.79 5.45% | 112.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-9.27 1.85% | 490.61 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-12.28 1.48% | 817.15 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases. The company primarily focuses on inhibitors of protein phosphatase 2A that are used in combination with cytotoxic agents and/or x-ray, immune checkpoint blockers and other cancer therapies. It develops LB-100 that has completed phase I clinical trial for advanced soft tissue carcinoma and small cell lung cancer, as well as is in Phase II clinical trial for ovarian clear cell cancer. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; license agreements with National Institute of Health and Moffitt Cancer Center; and collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
680 East Colorado Boulevard, Pasadena, CA, United States, 91101
| Name | Title | Year Born |
|---|---|---|
| Dr. John S. Kovach | Founder, Chairman, Pres & CEO | 1937 |
| Mr. Robert Neal Weingarten | VP & CFO | 1952 |
| Mr. Eric J. Forman J.D. | Chief Admin. Officer | 1980 |
| Dr. James S. Miser M.D. | Chief Medical Officer | 1947 |
| Mr. Gil N. Schwartzberg J.D., Esq. | Consultant | NA |
| Dr. Francis Johnson Ph.D. | Consultant | NA |
| Mr. Bastiaan van der Baan M.Sc. | President, CEO & Chairman of the Board of Directors | 1972 |
| Mr. Eric J. Forman J.D. | VP & COO | 1979 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...